Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sarepta Therapeutics
(NQ:
SRPT
)
146.03
+1.79 (+1.24%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,373,520
Open
147.72
Bid (Size)
143.20 (1)
Ask (Size)
148.93 (11)
Prev. Close
144.24
Today's Range
145.05 - 150.48
52wk Range
55.25 - 173.25
Shares Outstanding
93,148,652
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
26 Analysts Have This To Say About Sarepta Therapeutics
Today 11:00 EDT
Via
Benzinga
Sarepta Therapeutics to Announce Second Quarter 2024 Financial Results
Today 7:00 EDT
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Performance
YTD
+51.78%
+51.78%
1 Month
-6.84%
-6.84%
3 Month
+13.38%
+13.38%
6 Month
+21.19%
+21.19%
1 Year
+34.73%
+34.73%
More News
Read More
Here's How Much $1000 Invested In Sarepta Therapeutics 10 Years Ago Would Be Worth Today
July 18, 2024
Via
Benzinga
SAVA Stock Plunges as Cassava Sciences CEO Steps Down. What to Know.
July 17, 2024
Via
InvestorPlace
Jim Cramer Says Don't Sell Match Group: 'You've Just Got A Very, Very Smart Investor In There'
July 17, 2024
Via
Benzinga
Here's How Much $100 Invested In Sarepta Therapeutics 10 Years Ago Would Be Worth Today
July 04, 2024
Via
Benzinga
Expert Outlook: Sarepta Therapeutics Through The Eyes Of 25 Analysts
July 01, 2024
Via
Benzinga
Looking At Sarepta Therapeutics's Recent Unusual Options Activity
June 26, 2024
Via
Benzinga
Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives
July 17, 2024
From
Cassava Sciences, Inc.
Via
GlobeNewswire
After a Big Win, Is Sarepta Therapeutics Stock a Buy?
July 06, 2024
Via
The Motley Fool
Has Sarepta Therapeutics Become a No-Brainer Stock Buy After This Recent FDA News?
July 04, 2024
Via
The Motley Fool
Exposures
Product Safety
1 Soaring Growth Stock to Buy and Hold for 10 Years
July 03, 2024
Via
The Motley Fool
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 28, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Here's How Much You Would Have Made Owning Sarepta Therapeutics Stock In The Last 10 Years
June 24, 2024
Via
Benzinga
Is Pfizer's Pain Sarepta Therapeutics' Gain? Don't Bet on It.
June 26, 2024
Via
The Motley Fool
Sarepta Therapeutics Scores 90-Plus RS Rating On Muscular Dystrophy Approval
June 24, 2024
Via
Investor's Business Daily
Micron To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Monday
June 24, 2024
Via
Benzinga
DraftKings And Dell Were Among The 10 Biggest Large Cap Stock Gainers Last Week (June 16-June 22): Are These In Your Portfolio?
June 23, 2024
Via
Benzinga
Google Parent Alphabet At All-Time High, In Stock Spotlight: See New Names On IBD 50, Stock Spotlight And More
June 21, 2024
Via
Investor's Business Daily
Growth Stocks Leave Value Stocks In The Dust: 4 Reasons For Biggest Monthly Lead In Over A Year
June 21, 2024
Via
Benzinga
Nasdaq Moves Lower; FactSet Research Posts Upbeat Earnings
June 21, 2024
Via
Benzinga
Why Kaival Brands Innovations Shares Are Trading Lower By 47%? Here Are Other Stocks Moving In Friday's Mid-Day Session
June 21, 2024
Via
Benzinga
Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty
June 21, 2024
Via
Benzinga
Stocks Stall As Chip Sector Struggles To Rebound; Dollar Eyes 7-Week Peak, Gold, Bitcoin Retreat: What's Driving Markets Friday?
June 21, 2024
Via
Benzinga
Sarepta's Expanded FDA Approval For Elevidys Potentially Shaping Future FDA Reviews, Analyst Says
June 21, 2024
Via
Benzinga
Exposures
Product Safety
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.